Physician profile
Arpana Bansal
NPI 1033531884
$5,282.60
in general payments reported to CMS, 2019-2025
19 companies · $3,114 in 2025
The $3,114 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $233 · 2023: $934 · 2024: $1,002 · 2025: $3,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,049.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $2,369.68 | 2025 | Rapiblyk |
| Pfizer INC. | $415.91 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $340.78 | 2023-2025 | Rebyota |
| Alexion Pharmaceuticals, INC. | $309.69 | 2022-2025 | Ultomiris |
| Abbvie INC. | $225.22 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.37 | 2022-2025 | Xifaxan |
| Shionogi INC | $191.80 | 2022-2024 | Fetroja |
| Merck Sharp & Dohme LLC | $179.66 | 2022-2024 | Dificid, Zerbaxa, Verquvo |
| Vertex Pharmaceuticals Incorporated | $159.91 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.53 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $151.86 | 2022-2024 | Eliquis, Camzyos |
| Csl Behring | $145.95 | 2022-2024 | Kcentra |
| Aimmune Therapeutics, INC. | $145.78 | 2025 | Vowst |
| Insmed, INC. | $79.57 | 2023 | Arikayce |
| Janssen Pharmaceuticals, INC | $59.52 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $57.00 | 2022-2023 | Lokelma |
| Paratek Pharmaceuticals, INC. | $40.23 | 2024 | Nuzyra |
| Vifor Pharma, INC. | $37.78 | 2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $14.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpana Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.